RxDoctor Payments Data

Shaji Daniel, MD

Nephrology · Springfield, MANPI 1639384548

Payments from drug & device makers

$990in general payments, 2019–2025

Across 18 payments — averaging $54.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$317
  • AstraZeneca$156
  • Novo Nordisk$134
  • Calliditas Therapeutics US Inc.$125
  • Amgen$125
  • Vifor Pharma, Inc.$49
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$85686%
  • Education$13414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Baxter Healthcare3$317
AstraZeneca(2 entities)4$156
Novo Nordisk3$134
Calliditas Therapeutics US Inc.1$125
Amgen1$125
Vifor Pharma, Inc.2$49
Eurofins Viracor, LLC1$33
Sanofi1$19
GSK1$17
Alnylam Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$990 in reported general payments places this provider in the 60th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$100,000
Medicare patients
367
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$62,149
Envarsus XrTacrolimus28$53,593
EliquisApixaban14$20,168
FarxigaDapagliflozin Propanediol19$12,805
LokelmaSodium Zirconium Cyclosilicate16$8,175
Sevelamer Carbonate30$5,611
Nifedipine ErNifedipine81$2,446
Losartan Potassium152$2,264
Sodium Polystyrene Sulfonate38$1,908
Midodrine Hcl31$1,821
Amlodipine Besylate173$1,679
Mycophenolic AcidMycophenolate Sodium23$1,276
Carvedilol104$1,266
Hydralazine Hcl58$1,208
Lisinopril131$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$156$20,97935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →